12:00 AM
Aug 12, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Impavido miltefosine regulatory update

FDA's Anti-Infective Drugs Advisory Committee will meet on Oct. 18 to discuss an NDA for Impavido miltefosine from Paladin to treat leishmaniasis. The compound is under Priority Review with a Dec....

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >